| |
ABOUT THE BOOK:-
This collection of high–profile contributions provides a unique insight into the development of novel, successful biopharmaceuticals. Outstanding authors, including Nobel laureate Robert Huber as well as prominent company researchers and CEOs, present valuable insider knowledge, limiting their scope to those procedures and developments with proven potential for the biotechnology industry. They cover all relevant aspects, from the establishment of biotechnology parks, the development of successful compounds and the implementation of efficient manufacturing processes, right up to the establishment of advanced delivery routes. From the contents: • Modern biopharmaceuticals: research is the best medicine • Modern biopharmaceutical development using stem cells, tissues, and whole animals • Innovative development tools for modern biopharmaceuticals • The rise of monoclonal antibodies – the premium class of biopharmaceuticals • Smart solutions for global challenges – vaccine–based biopharmaceuticals • Modern biopharmaceuticals – the holy grail for health and wealth • From innovative tools to improved therapies – the success of second–generation biopharmaceuticals • Biopharmaceutical manufacturing and downstream processing – how to uncork bottlenecks
About the Author
Dr. Jörg Knäblein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max–Planck–Institute for Biochemistry. He received his Ph.D. from the Max–Planck–Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Robert Huber (Nobelprize laureate in 1988). Jörg Knäblein holds a leading position in technology scouting at Bayer Schering Pharma AG, Berlin. AWARDS: Riedel–de Haen–Stiftung Government / Ministry of Science Nomination for the Max–Buchner–Award from DECHEMA (Society for Biotechnology and Chemical Engineering) Winner of the McKinsey business plan contest ISBN - 9783527322831
|
| |
|